Discussion about this post

User's avatar
Virgil Brewster's avatar

This article is an amazing journey through the history of marketing.

The IVD Manager Evolution's avatar

A useful reminder that AI does not make marketing theory obsolete. It makes theory more important.

When execution becomes cheaper and faster, the real constraint shifts from production to judgement: which customer to serve, which problem to solve, which position to occupy, and which trade-offs to accept. That is why frameworks from Drucker, Levitt, Porter, Kotler, Christensen or Kahneman remain highly relevant even in an AI-driven environment. (Future of Marketing⁠)

I would add one important observation: some of these theories become even more powerful when applied to complex, regulated B2B markets.

Levitt’s Marketing Myopia is particularly relevant. An IVD company should not define itself as selling analysers, reagents or assays, but as helping laboratories improve diagnostic quality, workflow efficiency, clinical decision-making and operational resilience.

Jobs to Be Done is equally powerful. An IVD clinical laboratory does not “hire” a new diagnostic platform simply to run tests. It may be hiring it to reduce turnaround-time variability, compensate for staff shortages, standardise multiple sites, reduce reruns, mitigate regulatory risk or improve uptime.

Porter and STP also remain essential because specialised IVD companies cannot realistically compete everywhere. Choosing the right segment, and deliberately deciding where not to compete, is often more important than adding another campaign or another channel.

I would also give Prospect Theory a particularly important role in healthcare. In diagnostics, customers are highly loss- and risk-sensitive. The perceived risk of changing platforms, downtime, LIS integration, retraining, validation and disruption to patient care, may outweigh the promised upside of superior technology. Successful marketing therefore needs to reduce the perceived risk of change, not simply communicate more benefits.

If I were to add one theory to the list for healthcare and IVD, it would probably be Diffusion of Innovations. Diagnostic technologies rarely move directly from launch to broad adoption. KOLs, reference laboratories, early adopters, peer evidence and successful implementation sites strongly influence how the rest of the market reduces uncertainty and follows.

The broader lesson is compelling: AI can generate the artefact, but it cannot decide whether we are solving the right problem.

In complex markets, strategy still begins with theory, evidence and judgement, not with the prompt.

18 more comments...

No posts

Ready for more?